Inflammatory Bowel Disease (IBD) Expanded Profile
Also known as: Atypical pANCA, Glycominds, IBDX
Use
Aids in the diagnosis of inflammatory bowel disease (IBD) and the differential diagnosis of Crohn's disease (CD) and ulcerative colitis (UC); prognostic aid for clinical management of patients with CD.
Special Instructions
Not provided.
Limitations
Results of this panel should be used in conjunction with clinical findings and other laboratory tests. There are cases where patients with inflammatory bowel disease may be negative for both ASCA and pANCA. The addition of novel serological markers improves the sensitivity of the conventional ASCA/pANCA combination, though a definitive diagnosis often requires endoscopy with biopsies for histologic examination.
Methodology
Immunoassay (EIA)
Biomarkers
LOINC Codes
- 47321-5 - Baker's yeast IgG Qn IA
- 53594-8 - Chitobioside IgA SerPl IA-aCnc
- 53596-3 - Laminaribioside IgG SerPl IA-aCnc
- 53597-1 - Mannobioside IgG SerPl IA-aCnc
- 53029-5 - p-ANCA atypical Ser Ql IF
- 77202-0 - Laboratory comment Report
Result Turnaround Time
4-7 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
Red-top tube or gel-barrier tube
Storage Instructions
Refrigerate
Causes for Rejection
Hemolysis; lipemia; heat-treated specimen; gross bacterial contamination
Other tests from different labs that may be relevant